Registration Dossier

Diss Factsheets

Administrative data

Key value for chemical safety assessment

Additional information

Enpivalat (ZK 90504) did not show a mutagenic potential in a bacterial reverse mutation assay (Ames test in S. typhimurim strains TA 1535, TA 100, TA 1537, TA 1538 and TA98) when tested up to the highest recommended dose level of 5 mg/plate in the absense or presence of extrinsic metabolic activation (liver S9 mix from Aroclor 1254 -treated rats). Growth inhibition were observed at the highest dose tested. Precipitates in the agar were found starting at 2.5 mg/plate onwards.

Short description of key information:
Gene mutation (bacterial reverse mutation assay / Ames test, GLP, OECD TG471): negative with and without metabolic activation
[Schering AG, Report No. X390 -draft-, 2000-01-19]

Endpoint Conclusion: No adverse effect observed (negative)

Justification for classification or non-classification

Based on the results there is no classification required according to Directive 67/548/EEC and Regulation (EC) 1272/2008 (CLP).

Categories Display